Decreasing international HIV transmission: The role of expanding access to opioid agonist therapies for injection drug users

Addiction

Volumn 100, Issue 2, 2005, Pages 150-158

  Sullivan, Lynn E ^a   Metzger, David S ^b   Fudala, Paul J ^b   Fiellin, David A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Buprenorphine; HIV infections; Intravenous substance abuse; Methodone

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE; DIAMORPHINE; METHADONE; NALOXONE; OPIATE AGONIST;

COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG ABUSE; DRUG EFFICACY; DRUG USE; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTERNATIONAL COOPERATION; OPIATE ADDICTION; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

BUPRENORPHINE; DRUG EVALUATION; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; METHADONE; NARCOTIC ANTAGONISTS; NARCOTICS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 13844298368     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2004.00963.x     Document Type: Review

References (100)

1. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction (1998) Effective medical treatment of opiate addiction. Journal of the American Medical Association, 280, 1936-1943.
2. Gossop, M., Marsden, J., Stewert, D. & Treacy, S. (2002) Reduced injection risk and sex risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care, 14, 77-93.
3. Gibson, D. R., Flynn, N. M. & McCarthy, J. J. (1999) Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS, 13, 1807-1818.
4. Marsch, L. A. (1998) The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction, 93, 515-532.
5. Barnett, P. G. & Hui, S. S. (2000) The cost-effectiveness of methadone maintenance. Mount Sinai Journal of Medicine, 67, 365-374.
6. Gorsky, R. D., MacGowan, R. J. & Swanson, N. M. (1995) Prevention of HIV infection in drug abusers: a cost analysis. Preventive Medicine, 24, 3-8.
7. Zaric, G. S., Barnett, P. G. & Brandeau, M. L. (2000) HIV transmission and the cost-effectiveness of methadone maintenance, American Journal of Public Health, 90, 1100-1111.
8. Des Jarlais, D. C., Friedman, S. R. & Hopkins, W. (1985) Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Annals of Internal Medicine, 103, 755-759.
9. Des Jarlais, D. C., Paone, D., Friedman, S. R., Peyser, N. & Newman, R. G. (1995) Regulating controversial programs for unpopular people. Methadone maintenance and syringe exchange programs. American Journal of Public Health, 85, 1577-1584.
10. UNAIDS (2001) Drug abuse and HIV/AIDS: lessons learned. In: Joint United Nations Programme on HIV/AIDS, UNAIDS and United Nations Office for Drug Control and Crime Prevention. New York: United Nations.
11. Anonymous (2001) HIV Prevention Strategic Plan Through 2005. Centers for Disease Control and Prevention (CDC). http://www.cdc.gov.nchstp/od/news/ prevention.pdf [accessed 20 December 2004].
12. UNAIDS (2003) AIDS epidemic update - December 2003. In: Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO). Geneva, Switzerland: WHO.
13. UNAIDS (2003) 'HIV-AIDS Epidemic can be Prevented and Reversed Among Injecting Drug Users', says UNODC Head. In: United Nations Office on Drugs and Crime. Available from: http://www.unodc.org/unodc/en/ press_release_2003-12- 01_2.html [accessed 20 December 2004]. Vienna, Austria: United Nations Information Services.
14. Anonymous (2001) The global HIV and AIDS epidemic, 2001. Morbidity and Mortality Weekly Report, 50, 434-439.
15. Hein, N. (1995) Drug Use and HIV Infection in Viet Nam. Report of the WHO Drug Injecting Project Planning Meeting, Phase II. Bangkok, Thailand: WHO.
16. Department of Health Union of Myanmar (1993) AIDS Prevention and Control Programme 1993. Sentinel Surveillance Data. Yango: Ministry of Health.
17. World Health Organization (1997) STD/HIV/AIDS Surveillance Report: Special Edition. Report no. 10. Manila: WHO Regional Office for the Western Pacific.
18. UNAIDS (2001) HIV/AIDS: China's Titanic Peril. Update of the AIDS Situation and Needs Assessment Report, UNAIDS, Beijing. Beijing: China UN Theme Group on HIV/ AIDS for the UN Country Team in China.
19. Pokrovski, V. (1998) HIV Infections by Modes of Transmission in the Russian Federation. Report to UNAIDS. Russia AIDS Center.
20. Haverkos, H. W. (1998) HIV/AIDS and drug abuse: epidemiology and prevention. Journal of Addictive Diseases, 4, 91-103.
21. Hubbard, R. L., Marsden, M. E., Rachal, J. V., Harwood, H. J., Cavanaugh, E. R. & Ginzburg, H. M. (1989) Drug Abuse Treatment: a National Study of Effectiveness. Chapel Hill: University of North Carolina Press.
22. Hubbard, R. L., Craddock, S. G., Flynn, P. M., Anderson, J. & Etheridge, R. M. (1997) Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors. 11, 261-278.
23. Ball, J. C., Lange, W. R., Myers, C. P. & Friedman, S. R. (1988) Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health and Social Behavior, 29, 214-226.
24. Ball, J. C. & Ross, A. (1991) The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer-Verlag, Inc.
25. Mattick, R. P., Breen, C., Kimber, J. & Davoli, M. (2003) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence [update of Cochrane Database Systematic Review, 2002, 4, CD002209: PMID: 12519570]. Cochrane Database Systematic Review.
26. Caplehorn, J. R. & Ross, M. W. (1995) Methadone maintenance and the likelihood of risky needle sharing. International Journal of Addiction, 30, 685-698.
27. Metzger, D. S., Woody, G. E., McLellan, A. T., O'Brien, C. P., Druley, P., Navaline, H., Dephilippis, D., Stolley, P. & Abrutyn, E. (1993) Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes, 6, 1049-1056.
28. Wong, K., Lee, S., Lim, W. & Low, H. (2003) Adherence to methadone is associated with lower level of HIV-related risk behaviors in drug users. Journal of Substance Abuse Treatment, 24, 233-239.
29. McLellan, A. T., Arndt, I. O., Metzger, D. S., Woody, G. E. & O'Brien, C. P. (1993) The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association, 269, 1953-1959.
30. Avants, K., Margolin, A., Sindelar, J., Rounsaville, B., Schottenfeld, R. S., Stine, S., Cooney, N., Rosenheck, R. A., Shou-Hua, L. & Kosten, T. R. (1999) Day treatment versus enhanced standard methadone services for opioid dependent patients: a comparison of clinical efficacy and cost. American Journal of Psychiatry, 156, 27-33.
31. Booth, R. E., Crowley, T. & Zhang, Y. (1996) Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug and Alcohol Dependence, 42, 11-20.
32. Kwiatkowski, C. & Booth, R. E. (2001) Methadone maintenance as HIV risk reduction with street recruited injecting drug users. Journal of Acquired Immune Deficiency Syndrome, 26, 483-489.
33. Avants, K., Margolin, A., Sindelar, J., Rounsaville, B., Schottenfeld, R. S., Stine, S., Cooney, N., Rosenheck, R. A., Shou-Hua, L. & Kosten, T. R. (1999) Day treatment versus enhanced standard methadone services for opioid dependent patients: a comparison of clinical efficacy and cost. American Journal of Psychiatry, 156, 27-33.
34. Gottheil, E., Lundy, A., Weinstein, S. P. & Sterling, R. C. (1998) Does intensive outpatient cocaine treatment reduce AIDS risky behaviors? Journal of Addictive Diseases, 4, 61-69.
35. Thiede, H., Hagan, H. & Murrill, C. S. (2000) Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. Journal of Urban Health, 77, 331-344.
36. Centers for Disease Control (1984) Antibodies to a retrovirus etiologically associated with acquired immunodeficiency syndrome (AIDS) in populations with increased incidences of the syndrome. Morbidity and Mortality Weekly Report, 33, 377-379.
37. Novick, D. M., Kreek, M. J., Des Jarlais, D. C., Spira, T., Khuri, E., Ragunath, J., Kalyanaraman, V., Gelb, A. & Miescher, A. (1986) Abstract of clinical research findings: therapeutic and historical aspects. In: Harris, L. S., ed. Problems of Drug Dependence, 1985. NIDA Research Monograph 67. Washington, DC: National Institute on Drug Abuse.
38. Barthwell, A., Senay, E., Marks, R. & White, R. (1989) Patients successfully maintained with methadone escaped human immunodeficiency virus infection. Archives of General Psychiatry, 45, 957.
39. Novick, D. M., Joseph, H., Croxson, T. S., Salsitz, E. A., Wang, G., Richman, B. L., Poretsky, L., Keefe, J. B. & Whimbey, E. (1990) Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Archives of Internal Medicine, 150, 97-99.
40. Blix, O. & Gronbladh, L. (1991) Impact of methadone maintenance treatment on the spread of HIV among IV heroin addicts in Sweden. In: Loimer, N., Schmid, R., Springer, A., eds. Drug Addiction and AIDS, pp. 200-205. New York: Springer-Verlag.
41. Brown, L. S., Burkette, W. & Primm, B. J. (1988) Drug treatment and HIV seropositivity. New York State Journal of Medicine, 88, 156.
42. Friedman, S. R., Jose, B., Deren, S., Des Jarlais, D. C. & Neaigus, A. (1995) Risk factors for HIV seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. American Journal of Epidemiology, 142, 864-874.
43. Serpelloni, G., Carriere, M. P., Rezza, G., Morganti, S., Gomma, M. & Binkin, N. (1994) Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-controlled study. AIDS Care, 6, 215-220.
44. Moss, A. R., Vranizan, K., Gorter, R., Bachetti, P., Watters, J. & Osmond, D. (1994) HIV seroconversion in intravenous drug users in San Francisco 1985-90. AIDS, 8, 223-231.
45. Healey, A., Knapp, M., Marsden, J., Gossop, M. & Stewart, D. (2003) Criminal outcomes and costs of treatment services for injecting and non-injecting heroin users: evidence from a national prospective cohort survey. Journal of Health Services and Research Policy, 8, 134-141.
46. Bell, J., Mattick, R., Hay, A., Chan, J. & Hall, W. (1997) Methadone maintenance and drug-related crime. Journal of Substance Abuse, 9, 15-25.
47. Barnett, P. G. (1999) The cost-effectiveness of methadone maintenance as a health care intervention. Addiction, 94, 479-188.
48. Zaric, G. S. & Brandeau, M L. (2001) Optimal investment in a portfolio of HIV prevention programs. Medical Decision Making. 21, 391-108.
49. Metzger, D. S., Navaline, H. & Woody, G. E. (1998) Drug abuse treatment as AIDS prevention. Public Health Reports, 113, 97-106.
50. Metzger, D. S. & Navaline, H. (2003) Human immunodeficiency virus prevention and the potential of substance abuse treatment. Clinical and Infectious Disease, 37, S451-S456.
51. Sorensen, J. & Copeland, A. (2000) Drug abuse treatment as an HIV prevention strategy: a review. Drug and Alcohol Dependence, 59, 17-31.
52. Mazlan, M., Schottenfeld, R. S. & Chawarski, M. S. (2001) Effects of buprenorphine treatment on HIV risk behaviours. Drug and Alcohol Dependence. 63, S96.
53. Marsch, L. A., Bickel, W. K. & Jacobs, E. A, (1999) Efficacy of buprenorphine treatment in reducing drug-and sex-related HIV risk behaviour among opioid-dependent individuals. In: Harris, L. S., ed. Proceedings of the 61st Annual Scientific Meeting. NIDA Research Monograph no. 180, p. 327. Rockville, MD: NIDA.
54. Cooper, J. R. (1989) Methadone treatment and acquired immunodeficiency syndrome. Journal of the American Medical Association, 262, 1664-1668.
55. World Health Organization (1998) Harm reduction approaches to injecting drug use. Available from: http:// www.who.int/hiv/topics/harm/reduction/en/ print.html [accessed 17 December 2004].
56. United Nations (2000) A Position Paper of the United Nations Systems. IV Annex to the Report of the 8th Session of ACC Subcommittee on Drug Control, 28-29 September 2000. http://www.unaids.org/wac/2001/background/ HRAIDS.doc [accessed 20 December 2004]. Vienna, Austria: UNDCP, UNAIDS and WHO.
57. World Health Organization (WHO) (1996) Report on Consultation Meeting on WHO Drug Substitution Project. Report no. WHO/PSA/96.3. Geneva: Programme on Substance Abuse, WHO.
58. World Health Organization (WHO) Department of Mental Health and Substance Dependence (2002) The Practices and Context of Pharmacotherapy of Opiold Dependence in Southeast Asia and Western Pacific Regions. Available from: http://whqlibdoc.who.int/hq/2002/who_msd_msb_02. 1.pdf [accessed 17 December 2004].
59. Central and Eastern European Harm Reduction Network (2002) Injecting Drug Users HIV/AIDS Treatment and Primary Care in Central and Eastern Europe and the Former Soviet Union. Vilnius, Lithuania: Central and Eastern European Harm Reduction Network.
60. Ball, A. L., Rana, S. & Dehne, K. L. (1998) HIV prevention among injecting drug users: responses in developing and transitional countries. Public Health Reports, 113, 170-181.
61. Des Jarlais, C., Perlis, T., Friedman, S. R., Chapman, T., Kwok, J., Rockwell, R., Paone, D., Milliken, J. & Monterroso, E. (2000) Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City 1990-1997. American Journal of Public Health, 90, 1112-1116.
62. Jasinski, D. R., Pevnick, J. S. & Griffith, J. D. (1978) Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Archives of General Psychiatry, 35, 501-516.
63. Vastag, B. (2003) In-offlce opiate treatment 'not a panacea'. Physicians slow to embrace therapeutic option. Journal of the American Medical Association, 290, 731-735.
64. Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E. & Gilbert, P. E. (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. Journal of Pharmacology and Experimental Therapeutics, 197, 517-532.
65. Villiger, J. W. & Taylor, K. M. (1981) Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Sciences, 29, 2699-2708.
66. Sadee, W., Richards, M. L., Grevel, J. & Rosenbaum, J. S. (1983) In vivo characterization of four types of opioid binding sites in rat brain. Life Sciences, 33, 187-189.
67. Sadee, W., Rosenbaum, J. S. & Herz, A. (1982) Buprenorphine: differential interaction with opiate receptor subtypes in vivo. Journal of Pharmacology and Experimental Therapeutics, 223, 157-162.
68. Bloms-Funke, P., Gillen, C., Schuettler, A. J. & Wnendt, S. (2000) Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides, 21, 1141-1146.
69. Lee, K. O., Akil, H., Woods, J. H. & Traynor, J. R. (1999) Differential binding properties of oripavines at cloned muand delta-opioid receptors. European Journal of Pharmacology, 378, 323-330.
70. Rothman, R. B., Qu, N. & Heng, X. (1995) Buprenorphine: combating drug abuse with a unique opioid. In: Cowan, A. & Lewis, J. W., eds. Buprenorphine: A Review of the Binding Literature, pp. 19-29. New York: Wiley-Liss.
71. Fudala, P. J., Yu, E., Macfadden, W., Boardman, C. & Chiang, C. N. (1998) Effects of buprenorphine and naloxone interactions in morphine-stabilized opiate addicts. Drug and Alcohol Dependence, 50, 1-8.
72. Mendelson, J., Jones, R. T., Fernandez, I., Welm, S., Melby, A. K. & Baggott, M. J. (1996) Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clinical and Pharmacological Therapy, 60, 105-114.
73. Mendelson, J., Jones, R. T., Welm, S., Baggott, M., Fernandez, I., Melby, A. K. & Nath, R. P. (1999) Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology, 141, 37-16.
74. Mendelson, J., Jones, R. T., Welm, S., Brown, J. & Batki, S. L. (1997) Buprenorphine and naloxone interactions in methadone maintenance patients. Biological Psychiatry, 41, 1095-1101.
75. Stoller, K. B., Bigelow, G. E., Walsh, S. L. & Strain, E. C. (2001) Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology, 154, 230-242.
76. Comer, S. D. & Collins, E. D. (2002) Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. Journal of Pharmacology and Experimental Therapeutics, 303, 695-703.
77. Strain, E. C., Stoller, K., Walsh, S. L. & Bigelow, G. E. (2000) Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology, 148, 374-383.
78. Fiellin, D. A., Pantalon, M. V., Pakes, J. P., O'Connor, P. G., Chawarski, M. & Schottenfeld, R. S. (2002) Treatment of heroin dependence with buprenorphine in primary care. American Journal of Drug and Alcohol Abuse, 28, 231-241.
79. Amass, L., Kamien, J. B. & Mikulich, S. K. (2000) Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence, 58, 143-152.
80. McCance-Katz, E. F., Rainey, P. M., Friedland, G. & Jatlow, P. (2003) The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clinical Infectious Diseases, 37, 476-182.
81. Rainey, P. M., Friedland, G. H., Snidow, J. W., McCance-Katz, E. F., Mitchell, S. M., Andrews, L., Lane, B. & Jatlow, P. (2002) The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. American Journal on Addictions, 11, 66-74.
82. Rainey, P. M., Friedland, G., McCance-Katz, E. F., Andrews, L., Mitchell, S. M., Charles, C. & Jatlow, P. (2000) Interaction of methadone with didanosine and stavudine. Journal of Acquired Immune Deficiency Syndromes, 24, 241-248.
83. Gourevitch, M. N. & Friedland, G. H. (2000) Interactions between methadone and medications used to treat HIV infection: a review. Mount Sinai Journal of Medicine, 67, 429-436.
84. Carrieri, M. P., Vlahov, D., Dellamonica, P., Gallais, H., Lepeu, G., Spire, B. & Obadia, Y. (2000) Use of buprenorphine in HIV infected injection drug users: negligible impact on virological response to HAART. Drug and Alcohol Dependence, 60, 51-54.
85. Anonymous (2003) Drugs approved for opiate dependence. FDA Consumer, 37, 6.
86. Cohen, J., (2004) HIV/AIDS in China. Changing course to break the HIV-heroin connection. Science, 304, 1434-1435.
87. World Health Organization (WHO) (2002) Models of medication supported treatment for opioid addicts report. In: WHO Regional Office for Europe. http://www. heroinstudie.de/WHO_report.pdf [accessed 20 December 2004].
88. Sakoman, S. (2000) Substance abuse in the Republic of Croatia and National Program for Drug Control. Croatian Medical Journal, 41, 270-286.
89. Choopanya, K., Des Jarlais, D. C., Vanichseni, S., Mock, P. A., Kitayaporn, D., Sangkhum, D., Prasithiphol, B., Hiranus, K., van Griensven, F., Tappero, J. W. & Mastro, T. D. (2003) HIV risk reduction in a cohort of injecting drug users in Bangkok, Thailand. Journal of Acquired Immune Deficiency Syndromes, 33, 88-95.
90. Gossop, M. & Grant, M. (1991) A six country survey of the content and structure of heroin treatment programmes using methadone. British Journal of Addiction, 86, 1151-1160.
91. Lintzeris, N., Clark, N., Muhleisen, P., Ritter, A., Ali, R., Bell, J., Gowing, L., Hawkin, L., Henry, E. S., Mattick, R. P., Monheit, B., Newton, I., Quigley, A., Whicker, S. & White, J. (2001) Clinical guidelines: buprenorphine treatment of heroin dependence. Available from: http://www.health. vic.gov.au/dpu/downloads/bupguide.pdf [accessed 17 December 2004].
92. Department of Health, Scottish Office Department of Health (Welsh Office), Department of Health Social Services, Northern Ireland (1999) Drug Misuse and Dependence - Guidelines on Clinical Management, London: TSO.
93. Federation of State Medical Boards of the United States, (2002) I. Buprenorphine report of the center for substance abuse work group. In: SAMHSA. Available from: http:// www.buprenorphine.samhsa.gov/model.html [accessed 17 December 2004].
94. College of Physicians and Surgeons of Ontario (2001) Methadone Maintenance Guidelines. Available from: http:// www.cpso.on.ca/publications/ methguide.htm and http:// www.cpso.on.ca/publications/methadone%20guide.pdf [accessed 17 December 2004].
95. Fiellin, D. A., Storti, S. A., Schottenfeld, R. S., Biscoe, J. D., Pantalon, M. V. & O'Connor, P. G. (2000) Methadone medical maintenance: a training resource guide for office-based physicians. In: New England Addiction Technology Transfer Center, Center for Substance Abuse Treatment. Available from: http://www.attc-ne.org/pubs/ 1-84.ppt [accessed 17 December 2004].
96. Henry-Edwards, S., Gowing, L., White, J., Ali, R., Bell, J., Brough, R., Lintzeris, N., Ritter, A. & Quigley, A. (2003) Clinical Guidelines and Procedures for the Use of Methadone in the Maintenance Treatment of Opioid Dependence. Canberra.
97. Fiellin, D. A. & Barthwell, A. G. (2003) Guideline development for office-based pharmacotherapies for opioid dependence. Journal of Addictive Diseases, 22, 109-120.
98. Department of Health and Human Services/HRSA, HW/ AIDS Bureau (2004) An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Abuse Treatment in HIV Primary Care Settings. Health Resources and Services Administration. HIV/AIDS Bureau, Demonstration Project Development and Evaluation Branch, Special Projects of National Significance. Available from: ftp:// ftp.hrsa.gov/hrsa/04guidancehab/hrsa04078.pdf [accessed 17 December 2004].
99. World Health Organization (WHO) (1997) WHO Drug Substitution Project. Report of Meeting on Opioid Substitution Programmes in Asia: Kathmandu, Nepal, 10-14 February. Report no. WHO/M3A/PSA/98. Geneva: Programme on Substance Abuse, WHO.
100. China Ministry of Health and United Nations Theme Group in HIV/AIDS in China (1997) China Responds to AIDS: HIV/AIDS and Needs Assessment Report. Beijing: The Ministry and The Group.